RxDoctor Payments Data

Tracy Kelecava, NP

Adult Health · York, SCNPI 1487079877

Payments from drug & device makers

$682in general payments, 2019–2025

Across 23 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$287
  • Lilly USA, LLC$171
  • AstraZeneca$125
  • Amgen$38
  • Novo Nordisk$27
  • AbbVie$21
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$47570%
  • Education$20730%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$682 in reported general payments places this provider in the 45th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$67,282
Medicare patients
289
Services billed
1,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$27,905
EliquisApixaban25$27,649
OzempicSemaglutide14$25,941
TrulicityDulaglutide12$24,131
JanuviaSitagliptin Phosphate18$21,737
FarxigaDapagliflozin Propanediol22$21,730
SymbicortBudesonide/Formoterol Fumarate21$5,810
Wixela InhubFluticasone Propion/Salmeterol32$3,830
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$3,552
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,735
Atorvastatin Calcium280$2,078
Omeprazole153$1,640
Gabapentin109$1,618
Albuterol Sulfate HfaAlbuterol Sulfate67$1,475
Glipizide ErGlipizide61$1,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$125$27,54143 claims
Novo NordiskOzempic$27$25,94114 claims
Lilly USA, LLCTrulicity$171$24,13112 claims
AbbVieSynthroid$21$1,00118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 292 adult health providers in South Carolina.

Other adult health in York

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →